News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Audentes Therapeutics Announces Six Abstracts To Be Presented At The American Society Of Gene And Cell Therapy Meeting May 21-24, 2014


5/19/2014 6:51:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the presentation of results from ongoing preclinical studies of AT001 (AAV-MTM1), Audentes’ novel therapeutic in development for the treatment of X-linked Myotubular Myopathy (XLMTM). XLMTM is a rare, inherited disorder characterized by severe muscle weakness and respiratory impairment.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES